GenX Laboratories Inc.   Report issue

For profit Phase 2
Founded: Los Angeles CA United States (2011)

Organization Overview

First Clinical Trial
2017
NCT03316131
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

GenX Laboratories Inc.

Active Ingredients

Drugs in Phase 2 Trials (3)

dapagliflozin (farxiga) (1 trial)

febuxostat (uloric) (1 trial)

verinurad (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hyperuricemia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 3